Use of intravenous aminophylline in addition to the standard first-line treatment in children and adolescents with an acute asthma exacerbation: a systematic review and meta-analysis of randomised controlled trials
Open Access
- 25 June 2025
- journal article
- review article
- Published by BMJ in Archives of Disease in Childhood
- Vol. 110 (12) , 969-976
Abstract
Importance: The role of intravenous aminophylline in acute asthma in childhood is unclear. Objectives: To assess the safety and efficacy of intravenous aminophylline for asthma in children. Methods: From 1966 to May 2024, we searched MEDLINE, Embase, CINAHL, Web of Science and the Cochrane Central Register of Controlled Trials. We included only randomised controlled trials testing standard treatment in combination with aminophylline and followed the international guidelines for conducting systematic reviews. The outcomes measured were morbidity, escalation of care, length of hospital stay, adverse events, mortality and lung functions. We used the random-effects model for data analysis and the fixed-effects model to evaluate heterogeneity. Results: Nine studies (466 participants) fulfilled our a priori eligibility criteria. No significant difference was found in post-treatment asthma severity score (mean difference (MD)=0.13, 95% CI −0.79 to 1.06, I 2 =0 %), hospitalisation rate (risk ratio (RR)=0.66, 95% CI 0.27 to 1.59, I 2 =0 % ), paediatric intensive care unit admission (RR=0.73, 95% CI 0.51 to 1.05, I 2 =0%), intubation rate (RR=0.09, 95% CI 0.01 to 1.64, p=0.1) or length of hospital stay (MD=−3.62, 95% CI −13.05 to 5.82, I 2 =31%). Emesis (RR=3.52, 95% CI 2.04 to 6.06, I 2 =0%) and nausea (RR=4.92, 95% CI 2.41 to 10.06, I 2 =0%) occurred more in the aminophylline group. One study showed improved lung function in the aminophylline group, while others showed no difference. Conclusion: This review showed limited evidence of the benefit of intravenous aminophylline in managing asthma in most preventilation severity parameters. However, lowering the intubation rate and improving lung function deserve more attention. PROSPERO registration number: CRD42023405234.Keywords
This publication has 25 references indexed in Scilit:
- Early administration of two intravenous bolus of aminophylline added to the standard treatment of children with acute asthmaRespiratory Medicine, 2008
- Efficacy of IV Aminophylline as a Supplemental Therapy in Moderate Broncho-obstructive Crisis in Infants and Preschool ChildrenPulmonary Pharmacology & Therapeutics, 2000
- Randomised controlled trial of aminophylline for severe acute asthmaArchives of Disease in Childhood, 1998
- Efficacy of Aminophylline in the Treatment of Acute Asthma Exacerbation in ChildrenAnnals of Allergy, Asthma & Immunology, 1998
- Theophylline Does Not Shorten Hospital Stay for Children Admitted for AsthmaArchives of Pediatrics & Adolescent Medicine, 1995
- Efficacy of intravenously administered theophylline in children hospitalized with severe asthmaThe Journal of Pediatrics, 1993
- Hospital treatment of asthma: lack of benefit from theophylline given in addition to nebulized albuterol and intravenously administered corticosteroidThe Journal of Pediatrics, 1993
- Ipratropium BromideNew England Journal of Medicine, 1988
- The Pulmonary IndexAmerican Journal of Diseases of Children, 1984
- A Clinical Scoring System for the Diagnosis of Respiratory FailureAmerican Journal of Diseases of Children, 1972